Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Atzpodien

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Journal of the National Cancer Institute|May 1, 1996
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanomaU Kunter, J Buer, M Probst, et al.
Molecular Biotherapy|March 1, 1990
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient studyJ Atzpodien, A Körfer, P Evers, et al.
Cancer Biotherapy|January 1, 1993
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinomaP A Palmer, J Atzpodien, T Philip, et al.
British Journal of Haematology|February 1, 1994
Detection of clonal T-cell populations in gastrointestinal lymphomas by analysis of cRNA conformational polymorphisms of rearranged T-cell-receptor-gamma genesO M Koch, M Probst, M Tiemann, et al.
Experimental Cell Biology|January 1, 1988
Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex vivoJ Atzpodien, S C Gulati, J H Kwon, et al.
British Journal of Cancer|March 10, 2005
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, E Schmitt, U Gertenbach, et al.
British Journal of Cancer|November 17, 2001
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trialJ Atzpodien, H Kirchner, H J Illiger, et al.
British Journal of Clinical Pharmacology|August 5, 1998
Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous applicationG I Kirchner, A Franzke, J Buer, et al.
British Journal of Haematology|August 1, 1997
Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanomaM Probst-Kepper, A Schrader, J Buer, et al.
Annals of Hematology|October 24, 2000
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study GroupM Feuring-Buske, M Kneba, M Unterhalt, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Journal of the National Cancer Institute|May 1, 1996
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanomaU Kunter, J Buer, M Probst, et al.
Molecular Biotherapy|March 1, 1990
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient studyJ Atzpodien, A Körfer, P Evers, et al.
Cancer Biotherapy|January 1, 1993
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinomaP A Palmer, J Atzpodien, T Philip, et al.
British Journal of Haematology|February 1, 1994
Detection of clonal T-cell populations in gastrointestinal lymphomas by analysis of cRNA conformational polymorphisms of rearranged T-cell-receptor-gamma genesO M Koch, M Probst, M Tiemann, et al.
Experimental Cell Biology|January 1, 1988
Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex vivoJ Atzpodien, S C Gulati, J H Kwon, et al.
British Journal of Cancer|March 10, 2005
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, E Schmitt, U Gertenbach, et al.
British Journal of Cancer|November 17, 2001
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trialJ Atzpodien, H Kirchner, H J Illiger, et al.
British Journal of Clinical Pharmacology|August 5, 1998
Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous applicationG I Kirchner, A Franzke, J Buer, et al.
British Journal of Haematology|August 1, 1997
Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanomaM Probst-Kepper, A Schrader, J Buer, et al.
Annals of Hematology|October 24, 2000
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study GroupM Feuring-Buske, M Kneba, M Unterhalt, et al.
Pageof 12